Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma
收藏NIAID Data Ecosystem2026-03-09 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2175054
下载链接
链接失效反馈官方服务：
资源简介：
The primary goal of this Phase 1 study is to characterize the safety and tolerability of MGD007 and establish the maximum tolerated dose (MTD) and schedule of MGD007 administered to patients with metastatic colorectal carcinoma. Pharmacokinetics, pharmacodynamics, and the anti-tumor activity of MGD007 will also be assessed.
创建时间：
2014-10-15
